Microcurrent Stimulation Therapy for Age-Related Macular Degeneration

(i-SIGHT2 Trial)

The trial aims to test the safety and effectiveness of a new treatment using the i-Lumen AMD device for individuals with nonexudative age-related macular degeneration (AMD). It involves microcurrent therapy, a gentle electrical stimulation applied to the eye area. Participants will be divided into two groups: one will receive the actual therapy, while the other will receive a placebo with no active treatment. This study may suit those with nonexudative AMD and vision challenges typically associated with this condition, provided they do not have electrical implants or severe eye conditions like uncontrolled diabetes or glaucoma. As an unphased trial, it offers an opportunity to explore innovative treatments for nonexudative AMD.

The trial information does not specify if you need to stop taking your current medications. However, certain conditions and treatments, like glaucoma requiring multiple medications or recent photobiomodulation therapy, may affect eligibility.

Research has shown that the i-Lumen AMD device, used for microcurrent stimulation therapy, has undergone safety testing in people with age-related macular degeneration (AMD). These studies indicate that the treatment is generally well-tolerated, with most participants not experiencing serious side effects.

Some individuals have reported mild discomfort, such as slight tingling or warmth at the electrode sites. These sensations are usually temporary and do not cause long-term issues.

Unlike the standard treatments for age-related macular degeneration, which often include injections or laser therapy, i-Lumen AMD offers a non-invasive approach through microcurrent stimulation therapy. This therapy uses gentle electrical currents applied through the eyelids to potentially improve retinal function. Researchers are excited about i-Lumen AMD because it targets cellular processes in the eye without the need for surgery or injections, offering a potentially safer and more comfortable option for patients.

Research has shown that microcurrent stimulation therapy, such as the i-Lumen AMD device, may help treat dry age-related macular degeneration (AMD). In this trial, participants will receive either active i-Lumen AMD therapy or a sham therapy. Studies suggest that this therapy could improve vision or slow the disease's progression by using tiny electrical currents to stimulate the retina, the part of the eye that detects light. This stimulation is believed to enhance the function of the retinal pigment epithelium, which is crucial for eye health. Early findings indicate that microcurrent therapy might delay degeneration in both dry and wet forms of macular degeneration. While more research is needed, these initial results offer hope for people with this condition.¹²³⁵⁶